CTOs on the Move

Vision Service Plan

www.vspglobal.com

 
In 1955, a small group of optometrists had a vision to provide affordable, accessible, high-quality eye care to the world. They formed the first prepaid, not-for-profit vision benefit company, California Vision Services, the precursor to Vision Service Plan (VSP). That vision has evolved into VSP Global, with five complementary businesses that combine high-quality eye care insurance, high-fashion eyewear, customized lenses, ophthalmic technology and retail solutions to help people see around the globe.
  • Number of Employees: 1K-10K
  • Annual Revenue: > $1 Billion
  • www.vspglobal.com
  • 3333 Quality Drive
    Rancho Cordova, CA USA 95670
  • Phone: 916.851.5000

Executives

Name Title Contact Details
Steve Zickerman
 VP - CIO - CISO Profile

Similar Companies

Priority Pharmaceuticals

Priority Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

H2h Solutions

H2h Solutions, Inc is a Wixom, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied Health Care Services

We are committed to the people of our community, to help them overcome challenges and reach their greatest potential by providing quality care, people-oriented services and comfort.

Adnexus Therapeutics, Inc.

Adnexus Therapeutics, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Waltham, MA. To find more information about Adnexus Therapeutics, Inc., please visit www.adnexustx.com

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.